Skip to main content
main-content

24.01.2018 | Original Paper | Ausgabe 4/2018 Open Access

Acta Neuropathologica 4/2018

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

Zeitschrift:
Acta Neuropathologica > Ausgabe 4/2018
Autoren:
Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, Thierry Gorlia, Martin J. van den Bent, Khê Hoang-Xuan, Élodie Vauléon, Anja Gijtenbeek, Roelien Enting, Brian Thiessen, Olivier Chinot, Frédéric Dhermain, Alba A. Brandes, Jaap C. Reijneveld, Christine Marosi, Martin J. B. Taphoorn, Wolfgang Wick, Andreas von Deimling, Pim French, Roger Stupp, Brigitta G. Baumert, Monika E. Hegi
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00401-018-1810-6) contains supplementary material, which is available to authorized users.

Abstract

The optimal treatment for patients with low-grade glioma (LGG) WHO grade II remains controversial. Overall survival ranges from 2 to over 15 years depending on molecular and clinical factors. Hence, risk-adjusted treatments are required for optimizing outcome and quality of life. We aim at identifying mechanisms and associated molecular markers predictive for benefit from radiotherapy (RT) or temozolomide (TMZ) in LGG patients treated in the randomized phase III trial EORTC 22033. As candidate biomarkers for these genotoxic treatments, we considered the DNA methylome of 410 DNA damage response (DDR) genes. We first identified 62 functionally relevant CpG sites located in the promoters of 24 DDR genes, using the LGG data from The Cancer Genome Atlas. Then we tested their association with outcome [progression-free survival (PFS)] depending on treatment in 120 LGG patients of EORTC 22033, whose tumors were mutant for isocitrate dehydrogenase 1 or 2 (IDHmt), the molecular hallmark of LGG. The results suggested that seven CpGs of four DDR genes may be predictive for longer PFS in one of the treatment arms that comprised MGMT, MLH3, RAD21, and SMC4. Most interestingly, the two CpGs identified for MGMT are the same, previously selected for the MGMT-STP27 score that is used to determine the methylation status of the MGMT gene. This score was higher in the LGG with 1p/19q codeletion, in this and other independent LGG datasets. It was predictive for PFS in the TMZ, but not in the RT arm of EORTC 22033. The results support the hypothesis that a high score predicts benefit from TMZ treatment for patients with IDHmt LGG, regardless of the 1p/19q status. This MGMT methylation score may identify patients who benefit from first-line treatment with TMZ, to defer RT for long-term preservation of cognitive function and quality of life.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Neurologie & Psychiatrie

Kombi-Abonnement

Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.

e.Med Neurologie

Kombi-Abonnement

Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.

Zusatzmaterial
Supplementary material 1 (PDF 962 kb)
401_2018_1810_MOESM1_ESM.pdf
Supplementary material 2 (XLSX 31 kb)
401_2018_1810_MOESM2_ESM.xlsx
Supplementary material 3 (XLSX 29 kb)
401_2018_1810_MOESM3_ESM.xlsx
Supplementary material 4 (XLSX 41 kb)
401_2018_1810_MOESM4_ESM.xlsx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2018

Acta Neuropathologica 4/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

01.11.2018 | Schwerpunkt: Immunpathologie | Ausgabe 6/2018

Der prädiktive Wert der PD-L1-Diagnostik

22.10.2018 | Schwerpunkt: Immunpathologie | Ausgabe 6/2018

Digitale Pathologie in der Immunonkologie – Aktuelle Chancen und Herausforderungen

Überblick zur Analyse von Immunzellinfiltraten mittels Whole Slide Imaging

22.10.2018 | Schwerpunkt: Immunpathologie | Ausgabe 6/2018

Prognostische Bedeutung von Immunzellinfiltraten in der Tumorpathologie